Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

Urothelial carcinoma is the second most frequent genitourinary malignancy. Despite the poor prognosis, new treatment options have emerged and have expanded the therapeutic landscape for the disease. Although major improvements have been achieved, many patients experience rapid disease progression an...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontes, Mariane S, Vargas Pivato de Almeida, Daniel, Cavalin, Clarissa, Tagawa, Scott T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790156/
https://www.ncbi.nlm.nih.gov/pubmed/36575731
http://dx.doi.org/10.2147/OTT.S339348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790156/
https://www.ncbi.nlm.nih.gov/pubmed/36575731
http://dx.doi.org/10.2147/OTT.S339348

Ejemplares similares